Premium
Juvenile dermatomyositis: treatment with intravenous gammaglobulin
Author(s) -
COLLET K.,
DALAC S.,
MAERENS B.,
COURTOIS J.M.,
IZAC M.,
LAMBERT D.
Publication year - 1994
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1994.tb02906.x
Subject(s) - juvenile dermatomyositis , dermatomyositis , medicine , gamma globulin , refractory (planetary science) , juvenile , immunology , antibody , biology , genetics , astrobiology
Summary High‐dose intravenous gammaglobulin (IVGG) has proved to be effective in the treatment of a number of immune disorders. We report two patients with juvenile dermatomyositis (DM) who improved with IVGG therapy. These patients had become refractory to corticosteroids and had developed unacceptable steroid toxicity. We suggest that IVGG can be useful in the treatment of juvenile DM. by reducing steroid requirements, and replacing immunosuppressive drugs.